JP6386453B2 - インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 - Google Patents

インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 Download PDF

Info

Publication number
JP6386453B2
JP6386453B2 JP2015520349A JP2015520349A JP6386453B2 JP 6386453 B2 JP6386453 B2 JP 6386453B2 JP 2015520349 A JP2015520349 A JP 2015520349A JP 2015520349 A JP2015520349 A JP 2015520349A JP 6386453 B2 JP6386453 B2 JP 6386453B2
Authority
JP
Japan
Prior art keywords
cells
pancreatic
cell
lineage
reprogrammed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015520349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522281A (ja
JP2015522281A5 (cg-RX-API-DMAC7.html
Inventor
ラスト，ウィリアム，エル．
Original Assignee
セラクシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラクシス，インコーポレーテッド filed Critical セラクシス，インコーポレーテッド
Publication of JP2015522281A publication Critical patent/JP2015522281A/ja
Publication of JP2015522281A5 publication Critical patent/JP2015522281A5/ja
Application granted granted Critical
Publication of JP6386453B2 publication Critical patent/JP6386453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2015520349A 2012-06-26 2013-06-24 インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 Active JP6386453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26
US61/664,259 2012-06-26
PCT/US2013/047243 WO2014004341A1 (en) 2012-06-26 2013-06-24 Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018149816A Division JP6856586B2 (ja) 2012-06-26 2018-08-09 インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞

Publications (3)

Publication Number Publication Date
JP2015522281A JP2015522281A (ja) 2015-08-06
JP2015522281A5 JP2015522281A5 (cg-RX-API-DMAC7.html) 2016-08-04
JP6386453B2 true JP6386453B2 (ja) 2018-09-05

Family

ID=48746139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015520349A Active JP6386453B2 (ja) 2012-06-26 2013-06-24 インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞
JP2018149816A Active JP6856586B2 (ja) 2012-06-26 2018-08-09 インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018149816A Active JP6856586B2 (ja) 2012-06-26 2018-08-09 インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞

Country Status (16)

Country Link
US (2) US9968639B2 (cg-RX-API-DMAC7.html)
EP (2) EP2864473B1 (cg-RX-API-DMAC7.html)
JP (2) JP6386453B2 (cg-RX-API-DMAC7.html)
KR (2) KR102058259B1 (cg-RX-API-DMAC7.html)
CN (2) CN104640979B (cg-RX-API-DMAC7.html)
AU (2) AU2013280698B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031676A2 (cg-RX-API-DMAC7.html)
CA (1) CA2876677C (cg-RX-API-DMAC7.html)
DK (1) DK2864473T3 (cg-RX-API-DMAC7.html)
EA (2) EA033954B1 (cg-RX-API-DMAC7.html)
ES (1) ES2745704T3 (cg-RX-API-DMAC7.html)
IL (2) IL236346B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00281A (cg-RX-API-DMAC7.html)
PT (1) PT2864473T (cg-RX-API-DMAC7.html)
SG (1) SG11201408717XA (cg-RX-API-DMAC7.html)
WO (1) WO2014004341A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
US11484554B2 (en) * 2018-02-09 2022-11-01 Seraxis, Inc. Pancreatic cells for treating diabetes and methods of generating the same
CN112888778B (zh) * 2018-10-15 2025-06-03 埃维亚生命科学有限公司 通过低分子化合物由源自内胚层组织或器官的细胞制备干细胞/祖细胞的方法
IL293803A (en) * 2019-12-11 2022-08-01 Univ Tokyo Induction of proliferating pancreatic islet-like germ cells by transient expression of mycl and induction of differentiation into insulin-positive cells
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
IL316370A (en) 2022-04-15 2024-12-01 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
WO2024163938A1 (en) 2023-02-03 2024-08-08 Seraxis, Inc. Therapeutic cells and methods relating to the same
WO2025029826A1 (en) 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
AU2376200A (en) 1999-01-07 2000-07-24 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
CN100475953C (zh) 1999-12-06 2009-04-08 通用医疗公司 胰腺干细胞
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
WO2004023100A2 (en) 2002-09-06 2004-03-18 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
ATE437941T1 (de) 2003-06-20 2009-08-15 Vrije Universiteit Brussel Vub Verfahren zur erzeugung von beta-inselzellen aus exokrinen pankreaszellen
CA2581424A1 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
JP2009543580A (ja) * 2006-07-19 2009-12-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 細胞の再プログラミング用組成物、及びその用途
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
US8455251B2 (en) 2007-11-09 2013-06-04 Rnl Bio Co., Ltd. Method for isolating and culturing adult stem cells derived from human amniotic epithelium
WO2009128533A1 (ja) 2008-04-18 2009-10-22 国立大学法人名古屋大学 間葉系幹細胞およびその生産方法
CN102083964B (zh) * 2008-05-09 2013-06-12 格拉斯哥大学大学行政评议会 与基于细胞的疗法相关的材料和方法
US9683215B2 (en) * 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
EP2379577A4 (en) * 2008-12-23 2012-08-29 Vivoscript Inc COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING WITHOUT GENETIC MODIFICATION
WO2011032025A2 (en) * 2009-09-10 2011-03-17 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
AU2011250912A1 (en) * 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9394523B2 (en) * 2010-08-22 2016-07-19 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
KR101836855B1 (ko) * 2010-08-31 2018-04-19 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN103210082A (zh) * 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
WO2012044486A1 (en) * 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection

Also Published As

Publication number Publication date
IL236346B (en) 2019-06-30
EA201590088A1 (ru) 2015-04-30
PT2864473T (pt) 2019-09-27
JP6856586B2 (ja) 2021-04-07
CA2876677C (en) 2021-09-07
JP2015522281A (ja) 2015-08-06
KR102058259B1 (ko) 2019-12-23
EP2864473B1 (en) 2019-08-21
BR112014031676A2 (pt) 2017-10-31
US20150231181A1 (en) 2015-08-20
EA033954B1 (ru) 2019-12-13
CN113265370A (zh) 2021-08-17
IL236346A0 (en) 2015-02-26
EP3611255A1 (en) 2020-02-19
AU2013280698B2 (en) 2019-01-17
EP2864473A1 (en) 2015-04-29
US20130344594A1 (en) 2013-12-26
CA2876677A1 (en) 2014-01-03
IN2015DN00281A (cg-RX-API-DMAC7.html) 2015-06-12
AU2019202085A1 (en) 2019-04-18
US9474772B2 (en) 2016-10-25
EA201992135A1 (ru) 2020-02-05
KR20190141263A (ko) 2019-12-23
JP2018193394A (ja) 2018-12-06
IL266965A (en) 2019-07-31
DK2864473T3 (da) 2019-09-23
SG11201408717XA (en) 2015-02-27
ES2745704T3 (es) 2020-03-03
CN104640979A (zh) 2015-05-20
KR102174581B1 (ko) 2020-11-06
WO2014004341A1 (en) 2014-01-03
AU2013280698A1 (en) 2015-01-22
US9968639B2 (en) 2018-05-15
CN104640979B (zh) 2021-05-04
KR20150036059A (ko) 2015-04-07
IL266965B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
JP6856586B2 (ja) インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞
US20240309330A1 (en) Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US9115342B2 (en) Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
KR100973453B1 (ko) 인간 배아 줄기 세포에서 유래되는 연골세포 전구체
CN113015794A (zh) 包含用于条件性永生化的可控转基因的诱导多能细胞
US20240124843A1 (en) Functional feline pancreatic cells from adipose tissue
US20230078230A1 (en) Methods for the production of committed cardiac progenitor cells
EA045078B1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
KR20250163871A (ko) 치료 세포 및 이와 관련된 방법

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20151016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180809

R150 Certificate of patent or registration of utility model

Ref document number: 6386453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250